ADDEX THERAPEUTICS TO REPORT 2026 THIRD QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 25, 2026
Key Highlights
- ➤Addex (ADXN) will report 2026 third-quarter financial results November 25, 2026
- ➤CEO Tim Dyer will provide a business update and pipeline review
- ➤Addex selected a GABAB PAM candidate for substance use disorders
- ➤Addex holds an 8.5% equity interest in Neurosterix US Holdings
Expert Statements
Tim Dyer, CEO of Addex Therapeutics
“will provide a business update and review of the Addex product pipeline”
Geneva, Switzerland, November 20, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Third Quarter Financial Results on November 25, 2026. Tim Dyer, CEO, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EDT / 07:00 PDT) on November 25, 2026.
Title: Addex Therapeutics Reports 2026 Third Quarter financial results and Provides Corporate Update Date: November 25, 2026 Time: 16:00 CET (15:00 BST / 10:00 EST / 07:00 PST)
Get started
Create a free account to read the full story.
